Emergent BioSolutions reported $328.9M in Stock for its fiscal quarter ending in December of 2023.





Stock Change Date
Acadia Pharmaceuticals USD 40.36M 68.31M Sep/2026
Akebia Therapeutics USD 18.7M 5.68M Sep/2026
ALKERMES USD 261.1M 37.86M Sep/2026
Alnylam Pharmaceuticals USD 105.91M 8.8M Sep/2026
Amarin USD 158.85M 5.22M Sep/2026
ANI Pharmaceuticals USD 136.41M 6.74M Sep/2026
BioMarin Pharmaceutical USD 1.8B 13.54M Sep/2026
Coherus Biosciences USD 5.67M 842K Jun/2026
Emergent BioSolutions USD 328.9M 25.2M Dec/2023
Exelixis USD 29.87M 1.14M Sep/2026
Glaxosmithkline GBP 6.3B 143M Sep/2026
Heron Therapeutics USD 54.57M 2.33M Dec/2022
Ionis Pharmaceuticals USD 28.58M 22.26M Sep/2026
Lexicon Pharmaceuticals USD 276K 5K Mar/2026
Lonza CHF 1.68B 163M Dec/2025
Merck USD 6.16B 43M Sep/2026
Moderna USD 313M 33M Sep/2026
Myriad Genetics USD 30.6M 2.7M Jun/2026
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 66.1M 38.1M Sep/2026
Pacira USD 3.83B 3.69B Sep/2026
Pfizer USD 10.02B 77M Sep/2026
PTC Therapeutics USD 109.33M 17.98M Sep/2026
Sanofi EUR 24.12B 620M Jun/2026
Sarepta Therapeutics USD 876.12M 28.15M Sep/2026
United Therapeutics USD 201.9M 8.1M Sep/2026
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025